The first biotech recognition program focused on companies with the potential to change how pharma operates, not just discovering or developing a successful drug. If your organization is driving innovation and creating impact, apply for recognition by completing this application and selecting the category that best fits your work.

The top companies will be recognized in the annual Global Pharmaceutical Invention and Innovation Index and associated launch. Three award categories recognizing ground-breaking​ discovery and innovation​. Apply here:

The awards will be judged by a panel of experts representing various critical stakeholder perspectives:

Alexander Gray: ​Industry Expert

• Chief Medical Officer, IDEA Pharma ​
• Pharmaceutical strategy expert​, trained physician and immunologist​ has led over 100 clinical development programs, shaping strategy and positioning of biopharma assets from early-stage trials through to commercialization​.

Andrew Marshall: Biotechnology Expert

• Andrew Marshall is a Partner at Haystack Science
• He worked at Scion Life Sciences, a $310M early-stage venture therapeutics fund in New York City and for over two decades led Nature Biotechnology. He has written hundreds of articles and editorials about biotech in the trade and popular media, including The Economist. He is fractional CEO of 511 and an EIR at Memorial Sloan Kettering Cancer Center.

Elizabeth Van Sant Hoffman: Pharmaceutical Expert​

• Senior Vice President, Portfolio Management and Clinical Design and Delivery, Eli Lilly​
• Oversees portfolio and project management, clinical development, R&D strategy, decision sciences, and clinical design and capabilities​. Including the R&D Due Diligence for business development and the transition of acquired companies into Lilly, ensuring acquired teams and potential medicines are welcomed effectively and integrated with Lilly’s delivery capabilities, scientific depth, and innovation.

Emine Yurdusever Temizkan: Pharmaceutical Expert​

• Vice President, Global Lead for the Lung Cancer Portfolio at BioNTech
• Over 20 years of international leadership across biotechnology and pharmaceuticals. With a career spanning BioNTech, Merck KGaA and Sanofi, she combines scientific insight with commercial vision to shape oncology portfolios, lead global launches and translate breakthrough innovation into meaningful impact for patients.

Sam Williams: Strategic Investor

• Chairman, Director, Investor Life Sciences​. He is currently a Venture Partner at IP Group plc
• Sam has over 25 years’ experience in the biotechnology industry as an investor, director and equity analyst. He has served as Chairman and non-executive director of numerous public and private biotech companies, including Apollo Therapeutics, Genomics Ltd, Microbiotica, Storm Therapeutics and Istesso, where he is co-founder and Executive Chairman.

Categories:

Platform Pioneer​

For companies building technologies capable of generating multiple future medicines​

Examples​

• AI-first drug discovery​
• Synthetic biology​
• Gene editingplatforms​

Disease Challenger​

For companies tackling diseases considered difficult, neglected, or previously untreatable​

Examples​

• Rare diseases​
• Neurodegeneration​
• Aging-related diseases

Modality Disruptor​

For companies pioneering new therapeutic modalities​

Examples​

• In vivo editing​
• RNA medicines​
• Microbiometherapeutics​

We look forward to receiving your application, please register your interest in the form above.